Literature DB >> 22552912

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas.

Hadara Rubinfeld1, Ilan Shimon.   

Abstract

Non-functioning pituitary adenomas (NFPAs) comprise a heterogeneous group, which are considered the most common pituitary tumor. As no clinically hormone hypersecretion is apparent, non-functioning pituitary adenomas are often diagnosed only when they are large enough to cause tumor mass effects, such as hypopituitarism, visual field defects or headaches. Efficient medical therapy for NFPAs is currently unavailable and surgical treatment of these tumors is not always satisfactory. Characterization of signaling regulatory events in the context of NFPAs may enable the development of new attractive novel strategies. Although data regarding gene expression profiling of signaling pathways in NFPAs have accumulated, studies aimed at fine-classification of NFPAs-specific signaling regulatory mechanisms and feedback loops are scarce.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552912     DOI: 10.1007/s12020-012-9682-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  68 in total

1.  A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.

Authors:  Arvind Rishi; Mehar C Sharma; Chitra Sarkar; Deepali Jain; Manmohan Singh; Ashok Kumar Mahapatra; Veer Singh Mehta; Tapos Kumar Das
Journal:  Neurol India       Date:  2010 May-Jun       Impact factor: 2.117

2.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Authors:  F M Sirotnak; M F Zakowski; V A Miller; H I Scher; M G Kris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.

Authors:  N A Hibberts; D J Simpson; J E Bicknell; J C Broome; P R Hoban; R N Clayton; W E Farrell
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

4.  Enhanced protein kinase B/Akt signalling in pituitary tumours.

Authors:  M Musat; M Korbonits; B Kola; N Borboli; M R Hanson; A M Nanzer; J Grigson; S Jordan; D G Morris; M Gueorguiev; M Coculescu; S Basu; A B Grossman
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

5.  Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

Authors:  Erika Hubina; Alexandra M Nanzer; Matthew R Hanson; Enrica Ciccarelli; Marco Losa; Daniela Gaia; Mauro Papotti; Maria Rosaria Terreni; Sahira Khalaf; Suzanne Jordan; Sándor Czirják; Zoltán Hanzély; György M Nagy; Miklós I Góth; Ashley B Grossman; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2006-08       Impact factor: 6.664

6.  Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.

Authors:  H Padova; H Rubinfeld; M Hadani; Z R Cohen; D Nass; J E Taylor; M D Culler; I Shimon
Journal:  Mol Cell Endocrinol       Date:  2007-12-27       Impact factor: 4.102

7.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

8.  A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.

Authors:  Xun Zhang; Yunli Zhou; Kshama R Mehta; Daniel C Danila; Staci Scolavino; Stacey R Johnson; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro.

Authors:  S S Chaidarun; M C Eggo; M C Sheppard; P M Stewart
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

Review 10.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

View more
  19 in total

1.  Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Authors:  Allyson Booth; Tammy Trudeau; Crystal Gomez; M Scott Lucia; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2014-12

Review 2.  Pathogenesis of non-functioning pituitary adenomas.

Authors:  Maria Chiara Zatelli
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Morphometric characteristics, cell proliferation parameters and apoptosis indices do not correlate with tendency to relapse in non-functioning pituitary macroadenomas.

Authors:  R M Ruggeri; F Trimarchi; L Curtò
Journal:  Endocrine       Date:  2012-10-27       Impact factor: 3.633

4.  Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.

Authors:  Claudia Pivonello; Roberta Patalano; Domenico Solari; Renata S Auriemma; Federico Frio; Francesca Vitulli; Ludovica F S Grasso; Marialuisa Di Cera; Maria Cristina De Martino; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2018-07-31       Impact factor: 3.633

5.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

6.  The Pituitary Tumors and Their Tumor-Specific Microenvironment.

Authors:  M M Kameda-Smith; J -Q Lu
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.

Authors:  Kai Zhou; Tingrong Zhang; YanDong Fan; Guojia Du; Pengfei Wu; Dangmurenjiafu Geng
Journal:  Tumour Biol       Date:  2016-07-27

Review 8.  Association of craniopharyngioma and pituitary adenoma.

Authors:  Federica Guaraldi; Nunzia Prencipe; Valentina di Giacomo; Massimo Scanarini; Valentina Gasco; Marina Paola Gardiman; Alessandro M Berton; Ezio Ghigo; Silvia Grottoli
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

9.  HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.

Authors:  Maria Trovato; Maria Luisa Torre; Marta Ragonese; Angela Simone; Rosy Scarfì; Valeria Barresi; Giuseppe Giuffrè; Salvatore Benvenga; Flavio F Angileri; Giovanni Tuccari; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Salvatore Cannavò
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

Review 10.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.